Abstract: Maraviroc (UK-427857) is a pioneering, orally bioavailable small-molecule antagonist of the CCR5 chemokine receptor, originally developed and approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. As the first host-targeted antiretroviral drug, it functions as a "gate keeper" by blocking viral entry into host cells. Beyond its potent antiviral efficacy against CCR5-tropic (R5) HIV-1 strains, maraviroc exhibits significant pharmacological versatility, demonstrating neuroprotective, anti-inflammatory, and endothelial-protective properties. Current research is expanding its therapeutic applications beyond infectious diseases into oncology, central and peripheral nervous system injuries, and the management of immune reconstitution inflammatory syndrome (IRIS). This review synthesizes the pharmacological profile, molecular mechanisms, structure-activity relationships, limitations, and future perspectives of maraviroc based on recent literature.
1. Introduction
Despite the dramatic decline in HIV-1-related morbidity and mortality following the advent of highly active antiretroviral therapy (ART), the emergence of drug resistance and tolerability issues necessitated the development of novel therapeutic classes [1]. The discovery that the chemokine receptor CCR5 is the primary co-receptor for the majority of HIV-1 strains (R5 viruses) positioned it as an attractive target for antiretroviral drug development [1]. Maraviroc (UK-427857, MVC) was discovered by Pfizer Global Research and Development through high-throughput screening of a compound library [1]. It is a potent, selective, and orally bioavailable small-molecule inhibitor of the CCR5 receptor [1][6]. As the first host-targeted antiretroviral drug, maraviroc ventured into uncharted territory and received approval in 2007 for use in treatment-experienced patients with R5 HIV-1, and subsequently in 2009 for treatment-naive patients [1].
2. Pharmacological Activity
In the context of infectious diseases, maraviroc exhibits potent broad-spectrum antiviral activity against a wide range of R5 HIV-1 isolates [1][6]. Clinical proof-of-concept studies demonstrated that doses of ≥100 mg twice daily (BID) resulted in mean maximum HIV-1 RNA reductions of >1.5 log10 [1]. Beyond its antiviral efficacy, maraviroc has demonstrated significant protective effects on the vascular endothelium. In people living with HIV (PLWH), maraviroc reduces arterial stiffness, decreases inflammation in human coronary artery endothelial cells, and improves endothelial function markers such as brachial flow-mediated vasodilation (FMD) and carotid intima-media thickness (cIMT) [3].
Furthermore, maraviroc exhibits notable neuroprotective properties. In animal models of simian immunodeficiency virus and HIV-1 Tat transgenic mice, maraviroc reduced the activation of brain phagocytes, attenuated neuroinflammation, protected the blood-brain barrier (BBB) by preventing the loss of tight junction proteins, and reduced leukocyte infiltration into the brain [3]. It has also shown efficacy in models of traumatic brain injury (TBI), intracerebral hemorrhage (ICH), and cerebral ischemia/reperfusion injury [5]. In oncology, maraviroc has been repurposed to counteract the CCL5/CCR5 axis, successfully suppressing the growth and inducing apoptosis of acute lymphoblastic leukemia cells, blocking metastasis in basal breast cancer, and inhibiting microenvironment interactions in Hodgkin lymphoma [7].
3. Molecular Mechanism of Action
Maraviroc functions as a "gate keeper" or receptor antagonist at the host cell surface [2]. It binds specifically within the transmembrane pocket of the CCR5 receptor, acting as a slow-offset functional antagonist that stabilizes the receptor and prevents its internalization [1]. By occupying this pocket, maraviroc allosterically alters the receptor's conformation, successfully preventing the binding of the HIV-1 envelope glycoprotein (gp120) to the CCR5 co-receptor [2][4]. This blockade halts the subsequent conformational changes required for the viral fusion peptide (gp41) to insert into the host cell membrane, thereby preventing viral entry [2].
At the cellular level, maraviroc also modulates immune and endothelial interactions. It prevents HIV-induced upregulation and phosphorylation of cytoskeleton-associated proteins, thereby diminishing the viral-induced adhesion of monocytes to human brain microvascular endothelial cells and preventing HIV-1 infection of macrophages [3].
4. Structure-Activity Relationship (SAR)
The development of maraviroc involved an extensive medicinal chemistry effort. Following the initial identification of a promising hit via a chemokine radioligand-binding assay, almost 1000 molecules were synthesized and characterized [1]. The optimization process focused on maximizing potency against the CCR5 receptor, enhancing broad-spectrum antiviral activity, improving pharmacokinetic characteristics for oral bioavailability, and ensuring strict selectivity against other human cellular targets to minimize off-target toxicity [1]. The precise molecular interactions have been elucidated through the resolved crystal structure of the CCR5 chemokine receptor bound to maraviroc, which provides critical structural insights into how the inhibitor anchors within the transmembrane domain to exert its allosteric effects [4].
5. Current Limitations
Despite its clinical success, maraviroc has several notable limitations. First, it is exclusively active against CCR5-tropic (R5) HIV-1 strains. It provides no virologic benefit against CXCR4-using (X4) or dual-tropic viruses [1]. Consequently, its clinical use strictly requires a highly sensitive, commercially validated phenotypic or genotypic tropism assay (such as the Trofile assay) prior to prescription to ensure the absence of CXCR4-using minority populations [1]. Virologic failure under maraviroc therapy is often associated with the emergence of these pre-existing CXCR4-using viral populations under selective pressure [1].
Additionally, as a receptor antagonist that must act in the presence of target cells, maraviroc cannot actively attack or neutralize cell-free virions circulating in the blood. This results in a relatively lower drug utilization rate compared to theoretical protein- or peptide-based virus inactivators that can irreversibly inactivate virions before they reach the host cell [2].
6. Future Perspectives
The future therapeutic landscape for maraviroc is expanding rapidly. In infectious diseases, there is potential for synergistic combination therapies; for instance, combining maraviroc with novel bifunctional HIV-1 inactivators (such as 2DLT) has shown strong synergistic effects against HIV-1 infection [2]. Furthermore, maraviroc is being investigated for the management of immune reconstitution inflammatory syndrome (IRIS), particularly progressive multifocal leukoencephalopathy (PML)-associated IRIS, supported by the high expression of CCR5 on CD8+ T cells in these patients [8].
Beyond virology, the modulation of the CCL5/CCR5 axis by maraviroc holds significant promise in oncology and neurology. Clinical trials are currently evaluating its efficacy in blocking cancer metastasis, inhibiting tumor microenvironment interactions, and preventing cancer stem cell expansion [7]. In neurology, maraviroc has demonstrated the ability to reduce neuropathic pain and enhance the analgesic effectiveness of opioid drugs, suggesting that combined administration could reduce required opioid doses and minimize complication risks in patients with central or peripheral nervous system injuries [5].
